Interval change in fractional exhaled nitric oxide (FENO) reflects short-term change in adherence following electronic inhaler reminders
暂无分享,去创建一个
[1] M. Hew,et al. Electronic inhaler monitoring (EIM) for chronic airways disease: Development and application of a Multi-Dimensional Efficacy Framework. , 2021, The journal of allergy and clinical immunology. In practice.
[2] H. Rupani,et al. Using FeNO Measurement in Clinical Asthma Management. , 2021, Chest.
[3] C. Janson,et al. Importance of type and degree of IgE sensitisation for defining fractional exhaled nitric oxide reference values. , 2021, Respiratory medicine.
[4] L. Kaye,et al. Digital Assessment of Medication Utilization by Age and Diagnosis of Asthma or COPD. , 2020, The journal of allergy and clinical immunology. In practice.
[5] S. Fowler,et al. Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: A literature review , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[6] P. Bradding,et al. Clinical outcomes in people with difficult-to-control asthma using electronic monitoring to support medication adherence. , 2020, The journal of allergy and clinical immunology. In practice.
[7] A. Bush,et al. Electronic adherence monitoring identifies severe preschool wheezers who are steroid responsive , 2020, Pediatric pulmonology.
[8] M. Mantero,et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. , 2020, Respiratory medicine.
[9] A. Nanzer,et al. Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma , 2020, European Respiratory Journal.
[10] M. Hew,et al. Trajectory analyses of adherence patterns in a real-life moderate to severe asthma population. , 2019, The journal of allergy and clinical immunology. In practice.
[11] R. Gerth van Wijk,et al. Toward clinically applicable biomarkers for asthma: An EAACI position paper , 2019, Allergy.
[12] R. Chaudhuri,et al. Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study , 2019, Thorax.
[13] J. Virchow,et al. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma , 2018, Thorax.
[14] O. Usmani,et al. Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here? , 2018, The journal of allergy and clinical immunology. In practice.
[15] T. Oguri,et al. Combined measurements of fractional exhaled nitric oxide and nasal nitric oxide levels for assessing upper airway diseases in asthmatic patients , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.
[16] L. Sharma,et al. Relationship between total serum immunoglobulin E levels, fractional exhaled breath nitric oxide levels and absolute blood eosinophil counts in atopic and non-atopic asthma: a controlled comparative study , 2018, Journal of breath research.
[17] P. Brand,et al. Can exhaled nitric oxide fraction predict adherence to inhaled corticosteroids in atopic and nonatopic children with asthma? , 2017, The journal of allergy and clinical immunology. In practice.
[18] C. Porsbjerg,et al. Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study , 2016, Respiratory Research.
[19] S. Hazen,et al. Biomarker-based asthma phenotypes of corticosteroid response. , 2015, The Journal of allergy and clinical immunology.
[20] R. Lutter,et al. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma , 2014, Thorax.
[21] B. Lipworth,et al. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. , 2012, Chest.
[22] R. Naclerio,et al. Criteria to screen for chronic sinonasal disease. , 2009, Chest.
[23] P. Barnes,et al. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children , 2003, European Respiratory Journal.
[24] P. Montuschi,et al. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma , 2002, Thorax.
[25] M. Griese,et al. Changes of exhaled nitric oxide during steroid treatment of childhood asthma , 1999, European Respiratory Journal.
[26] Arthur S Slutsky,et al. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. , 2001, Chest.